Published in Ann Noninvasive Electrocardiol on May 03, 2013
A high-risk patient with long-QT syndrome with no response to cardioselective beta-blockers. Heart Vessels (2014) 0.78
"QT clock" to improve detection of QT prolongation in long QT syndrome patients. Heart Rhythm (2015) 0.75
High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment "failures". Circulation (2008) 2.83
Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ Res (2002) 2.66
The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome. Circulation (2006) 2.58
Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation (2003) 2.56
Defining the cellular phenotype of "ankyrin-B syndrome" variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes. Circulation (2007) 2.38
Clinical aspects and prognosis of Brugada syndrome in children. Circulation (2007) 2.29
Characteristics of recurrent ventricular fibrillation associated with inferolateral early repolarization role of drug therapy. J Am Coll Cardiol (2009) 2.21
Cardiac characteristics and long-term outcome in Andersen-Tawil syndrome patients related to KCNJ2 mutation. Europace (2013) 2.14
Impact of the control of symptomatic paroxysmal atrial fibrillation on health-related quality of life. Europace (2010) 2.12
Long-term follow-up of asymptomatic Brugada patients with inducible ventricular fibrillation under hydroquinidine. Europace (2013) 2.02
Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J (2005) 1.99
Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace (2013) 1.97
MOG1: a new susceptibility gene for Brugada syndrome. Circ Cardiovasc Genet (2011) 1.97
Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol (2011) 1.89
Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet (2013) 1.86
Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation (2009) 1.76
Clinical assessment of drug-induced QT prolongation in association with heart rate changes. Clin Pharmacol Ther (2005) 1.74
Dominant-negative effect of SCN5A N-terminal mutations through the interaction of Na(v)1.5 α-subunits. Cardiovasc Res (2012) 1.74
R231C mutation in KCNQ1 causes long QT syndrome type 1 and familial atrial fibrillation. Heart Rhythm (2010) 1.71
Cardiac resynchronisation as a rescue therapy in patients with catecholamine-dependent overt heart failure: results from a short and mid-term study. Eur J Heart Fail (2008) 1.68
Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human. Hum Mol Genet (2012) 1.64
Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum (2003) 1.59
The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification. Circulation (2007) 1.58
Female predominance and transmission distortion in the long-QT syndrome. N Engl J Med (2006) 1.55
The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands. Europace (2012) 1.54
Usefulness of frequent arrhythmias after epicardial recanalization in anterior wall acute myocardial infarction as a marker of cellular injury leading to poor recovery of left ventricular function. Am J Cardiol (2003) 1.49
A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet (2011) 1.48
Clinical implications of "pure" Hisian pacing in addition to para-Hisian pacing for the diagnosis of supraventricular tachycardia. Heart Rhythm (2006) 1.44
The effect of atropine on rhythm and conduction disturbances during 322 critical care intubations. Pediatr Crit Care Med (2013) 1.44
High-flow perfusion of sheaths for prevention of thromboembolic complications during complex catheter ablation in the left atrium. J Cardiovasc Electrophysiol (2004) 1.43
Ventricular repolarization restitution properties in patients exhibiting type 1 Brugada electrocardiogram with and without inducible ventricular fibrillation. J Am Coll Cardiol (2008) 1.42
Contraction delay of the RV outflow tract in patients with Brugada syndrome is dependent on the spontaneous ST-segment elevation pattern. Heart Rhythm (2011) 1.39
Microvolt T-wave alternans in short QT syndrome. Pacing Clin Electrophysiol (2012) 1.39
Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm (2013) 1.33
Long QT syndrome in neonates: conduction disorders associated with HERG mutations and sinus bradycardia with KCNQ1 mutations. J Am Coll Cardiol (2004) 1.30
Novel calmodulin mutations associated with congenital arrhythmia susceptibility. Circ Cardiovasc Genet (2014) 1.27
Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol (2004) 1.19
Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation (2005) 1.15
Catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol (2012) 1.12
Germline and somatic mosaicism for a mutation of the ryanodine receptor type 2 gene: implication for genetic counselling and patient caring. Europace (2010) 1.11
Mutational spectrum in the Ca(2+)--activated cation channel gene TRPM4 in patients with cardiac conductance disturbances. Hum Mutat (2011) 1.07
24-hour BP in children with congenital central hypoventilation syndrome. Chest (2003) 1.06
Repolarization variability in the risk stratification of MADIT II patients. Europace (2007) 1.06
Identification of a KCNQ1 polymorphism acting as a protective modifier against arrhythmic risk in long-QT syndrome. Circ Cardiovasc Genet (2013) 1.03
Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. Arthritis Rheum (2004) 1.01
Diagnostic performance of a dual-chamber cardioverter defibrillator programmed with nominal settings: a European prospective study. J Cardiovasc Electrophysiol (2002) 0.94
Genotype- and Sex-Specific QT-RR Relationship in the Type-1 Long-QT Syndrome. J Am Heart Assoc (2012) 0.92
New KCNQ1 mutations leading to haploinsufficiency in a general population; Defective trafficking of a KvLQT1 mutant. Cardiovasc Res (2004) 0.92
Diagnosis and management of out-of-hospital cardiac arrest secondary to coronary artery spasm. Resuscitation (2003) 0.91
Tracing the European course of cardiac resynchronization therapy from 2006 to 2008. Europace (2010) 0.91
Spironolactone improves carotid artery fibrosis and distensibility in rat post-ischaemic heart failure. J Mol Cell Cardiol (2005) 0.89
Epidemiology of atrial fibrillation in France: extrapolation of international epidemiological data to France and analysis of French hospitalization data. Arch Cardiovasc Dis (2011) 0.89
Influence of cardiac autonomic neuropathy on heart rate dependence of ventricular repolarization in diabetic patients. Diabetes Care (2002) 0.87
Beat-to-beat T-wave amplitude variability in the long QT syndrome. Europace (2010) 0.87
Death due to an implantable cardioverter defibrillator. J Cardiovasc Electrophysiol (2004) 0.86
Usefulness of ventricular repolarization dynamicity in predicting arrhythmic deaths in patients with ischemic cardiomyopathy (from the European Myocardial Infarct Amiodarone Trial). Am J Cardiol (2005) 0.86
Short-long-short sequence caused by ventricular safety pacing inducing ventricular tachycardia in a patient with a dual-chamber implantable cardioverter defibrillator. Europace (2008) 0.85
T-wave morphology parameters based on principal component analysis reproducibility and dependence on T-offset position. Ann Noninvasive Electrocardiol (2007) 0.84
Short QT syndrome. Update on a recent entity. Arch Cardiovasc Dis (2008) 0.83
Magnitude, mechanism, and reproducibility of QT interval differences between superimposed global and individual lead ECG complexes. Ann Noninvasive Electrocardiol (2007) 0.83
Automatic ECG wave extraction in long-term recordings using Gaussian mesa function models and nonlinear probability estimators. Comput Methods Programs Biomed (2007) 0.82
Heart rate influences on repolarization duration and morphology in symptomatic versus asymptomatic KCNQ1 mutation carriers. Am J Cardiol (2005) 0.82
Quantitative assessment of ST segment elevation in Brugada patients. Heart Rhythm (2006) 0.81
Functional analysis reveals splicing mutations of the CASQ2 gene in patients with CPVT: implication for genetic counselling and clinical management. Hum Mutat (2011) 0.81
High take-off left inferior pulmonary vein as an obstacle in creating a conduction block at the lateral mitral isthmus. Europace (2009) 0.80
Automatic analysis of cardiac repolarization morphology using Gaussian mesa function modeling. J Electrocardiol (2008) 0.79
High-risk long QT syndrome mutations in the Kv7.1 (KCNQ1) pore disrupt the molecular basis for rapid K(+) permeation. Biochemistry (2012) 0.79
Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life-threatening ventricular arrhythmia. Int J Cardiol (2011) 0.79
Decreased nocturnal standard deviation of averaged NN intervals. An independent marker to identify patients at risk in the Brugada Syndrome. Eur Heart J (2003) 0.78